By Business/Source
Currency:CNY
2025/FY
Stock NameRevenueRatio
Authorized income9.43B53.27%
Sale of biopharmaceuticals8.01B45.24%
合同开发与生产运营业务263.48M1.49%
By Product
Currency:CNY
2025/FY
Stock NameRevenueRatio
Authorized income9.43B53.27%
Sale of biopharmaceuticals8.01B45.24%
合同开发与生产运营业务263.48M1.49%
By Country/Region
Currency:CNY
2025/FY
Stock NameRevenueRatio
United States of America9.52B53.77%
The mainland of China7.91B44.70%
Other countries / regions270.43M1.53%
